Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Talphera Inc TLPH

Healthcare

Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the... see more

Add To Watchlist

Recent & Breaking News (NDAQ:TLPH)

AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023

PR Newswire October 26, 2023

AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study

PR Newswire October 3, 2023

AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference

PR Newswire September 6, 2023

AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire August 10, 2023

AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

PR Newswire July 27, 2023

AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules

PR Newswire July 21, 2023

AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

PR Newswire July 18, 2023

AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire May 10, 2023

AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023

PR Newswire April 27, 2023

AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals

PR Newswire April 5, 2023

AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire March 30, 2023

AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023

PR Newswire March 21, 2023

AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals

PR Newswire March 14, 2023

AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures

PR Newswire March 1, 2023

AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock

PR Newswire December 27, 2022

AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine

PR Newswire December 8, 2022

AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire November 14, 2022

AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022

PR Newswire November 3, 2022

AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022

PR Newswire October 31, 2022

AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant

PR Newswire October 27, 2022